Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $3.8700 (4.59%) ($3.8700 - $3.8700) on Wed. Mar. 2, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.17% (three month average) | RSI | 30 | Latest Price | $3.8700(4.59%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | AUTL declines -7.9% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) XBI(66%) IBB(62%) IBUY(55%) IWO(53%) XRT(52%) | Factors Impacting AUTL price | AUTL will decline at least -2.085% in a week (0% probabilities). VIXM(-50%) TLT(-28%) VXX(-26%) TIP(-26%) SHY(-26%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.085% (StdDev 4.17%) | Hourly BBV | 1.5 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-8.94(-331.01%) | Resistance Level | $4.19 | 5 Day Moving Average | $3.84(0.78%) | 10 Day Moving Average | $4.02(-3.73%) | 20 Day Moving Average | $4.19(-7.64%) | To recent high | -43.7% | To recent low | 4.6% | Market Cap | $202m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |